Bill Horton, a partner in the Birmingham office and co-leader of the Healthcare Industry Team, was quoted in the Modern Healthcare article “CHS’ Texas hospital sales could raise costs, lower quality: FTC” about the Federal Trade Commission’s (FTC) comments in opposition two proposed hospital sales that that the FTC alleges could have detrimental effects on hospital quality and access in Texas. Bill comments that the change in Herfindahl-Hirschman Index, a measure of post-merger market concentration used by FTC, is significant in both proposed transactions.